Cartesian clears an autoimmune CAR-T trial, starts another Phase 2 and raises $130M

Kyle LaHucik

Senior Reporter

Cartesian Therapeutics, an mRNA cell therapy biotech, said its lead investigational medicine helped patients with an autoimmune condition that has caught the attention of many …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Cartesian clears an autoimmune CAR-T trial, starts another Phase 2 and raises $130M

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Carte­sian clears an au­toim­mune CAR-T tri­al, starts an­oth­er Phase 2 and rais­es $130M

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Cartesian clears an autoimmune CAR-T trial, starts another Phase 2 and raises $130M